triazoles has been researched along with aplaviroc in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goebel, FD; Horster, S | 1 |
| Emmelkamp, JM; Rockstroh, JK | 1 |
| Bredeek, UF; Harbour, MJ | 1 |
| Dioszegi, M; Ji, C; Kondru, R; Mirzadegan, T; Rotstein, D; Sankuratri, S; Zhang, J | 1 |
| de la Tribonnière, X; Reynes, J; Yazdanpanah, Y | 1 |
| Arenzana-Seisdedos, F | 1 |
| Arribas López, JR | 1 |
| Ghosh, AK; Kamata, W; Kruhlak, M; Li, J; Maeda, K; Mitsuya, H; Nakata, H; Ogata-Aoki, H | 1 |
5 review(s) available for triazoles and aplaviroc
| Article | Year |
|---|---|
Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
Topics: Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Treatment Outcome; Triazoles | 2006 |
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Topics: Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Interactions; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Triazoles | 2007 |
CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Cyclohexanes; Diketopiperazines; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Spiro Compounds; Triazoles | 2007 |
[Viral entry as therapeutic target. Current situation of entry inhibitors].
Topics: Adult; Amides; Benzoates; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Chemokines, CXC; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Models, Molecular; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Spiro Compounds; Structure-Activity Relationship; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
Topics: Adult; Benzoates; CCR5 Receptor Antagonists; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Comorbidity; Cyclohexanes; Diketopiperazines; Disease Susceptibility; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV Fusion Inhibitors; HIV Infections; Homozygote; Humans; Hyperlipidemias; Incidence; Infections; Maraviroc; Membrane Fusion; Neoplasms; Piperazines; Receptors, CCR5; Sequence Deletion; Spiro Compounds; Triazoles; Virus Attachment; Virus Internalization | 2008 |
3 other study(ies) available for triazoles and aplaviroc
| Article | Year |
|---|---|
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Topics: Amides; Amino Acid Sequence; Animals; Anti-HIV Agents; Benzoates; Binding Sites; CCR5 Receptor Antagonists; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Maraviroc; Membrane Fusion; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutagenesis, Site-Directed; Piperazines; Piperidines; Protein Structure, Secondary; Protein Structure, Tertiary; Pyrimidines; Quaternary Ammonium Compounds; Radioligand Assay; Receptors, CCR5; Sequence Homology, Amino Acid; Spiro Compounds; Static Electricity; Transfection; Triazoles | 2008 |
[CCR5 antagonists: a new class of antiretrovirals].
Topics: Benzoates; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Piperazines; Pyrimidines; Spiro Compounds; Triazoles | 2008 |
Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
Topics: Animals; Anti-HIV Agents; Bacterial Proteins; Benzoates; CCR5 Receptor Antagonists; Cell Line; Chemokine CCL5; Chemokines, CC; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Diketopiperazines; Fluorescence Recovery After Photobleaching; HIV Fusion Inhibitors; Humans; Luminescent Proteins; Maraviroc; Piperazines; Receptors, CCR5; Spiro Compounds; Triazoles | 2010 |